Back to Search Start Over

Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders

Authors :
Tycel Phillips
Sumana Devata
Ryan A. Wilcox
Source :
Journal for ImmunoTherapy of Cancer, Vol 4, Iss 1 (2016)
Publication Year :
2016
Publisher :
BMJ Publishing Group, 2016.

Abstract

The T-cell lymphoproliferative disorders are a heterogeneous group of non-Hodgkin’s lymphomas (NHL) for which current therapeutic strategies are inadequate, as most patients afflicted with these NHL will succumb to disease progression within 2 years of diagnosis. Appreciation of the genetic and immunologic landscape of these aggressive NHL, including PD-L1 (B7-H1, CD274) expression by malignant T cells and within the tumor microenvironment, provides a strong rationale for therapeutic targeting this immune checkpoint. While further studies are needed, the available data suggests that responses with PD-1 checkpoint blockade alone will unlikely approach those achieved in other lymphoproliferative disorders. Herein, we review the unique challenges posed by the T-cell lymphoproliferative disorders and discuss potential strategies to optimize checkpoint blockade in these T-cell derived malignancies.

Details

Language :
English
ISSN :
20511426
Volume :
4
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Journal for ImmunoTherapy of Cancer
Publication Type :
Academic Journal
Accession number :
edsdoj.32ced5c385b49be9f53c5ca0aa78931
Document Type :
article
Full Text :
https://doi.org/10.1186/s40425-016-0201-6